ObjectiveTo investigate the clinical efficacy of strontium chloride (89SrCl2) combined with external irradiation in the treatment of malignant tumor with large bone metastasis. MethodsA total of 100 patients with malignant tumor bone metastasis were selected as the research object and divided into group A (33 cases), group B (33 cases) and group C (34 cases) according to the random number table method. Group A was treated with external irradiation, group B was treated with 89SrCl2 and group C was treated with 89SrCl2 combined with external irradiation. The pain efficacy, physical status efficacy, metastatic lesion efficacy, survival quality and adverse reactions were compared among the three groups. ResultsThe total effective rate of pain relief, physical status improvement, and metastasis improvement in group C were higher than those in groups A and group B (all P＜0.05), but there was no statistically significant difference in the above indicators between group A and group B (all P＞0.05). After treatment, The EORTC QLQ-C30 scores of the three groups were higher than those before treatment, which was higher in group C than in group A and group B (all P＜0.05), but there was no statistically significant difference between group A and group B (P＞0.05). There were no statistically significant differences in the incidence of platelet (PLT) reduction and white blood cell (WBC) reduction among the three groups (all P＞0.05). ConclusionThe combination of 89SrCl2 and external irradiation is safe and effective in the treatment of malignant tumor bone metastasis, which can shrink tumor lesions, relieve patients′ pain, improve patients′ physical condition and survival quality, and there is no increase in toxic side effects.

无